FDA Investigator Rashmi Rawat, PhD
Rashmi Rawat, PhD has conducted inspections on 3 sites in 2 countries as of 19 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
3
Last Inspection Date:
19 Jun 2024
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America,
Denmark
FDA Investigators that have inspected at least one site in common with Rashmi Rawat, PhD:
Ann L Demarco,
Bo Chi, PhD,
Brandon C Heitmeier,
Brenda W Uratani, PhD,
Brian M Janelsins, PhD,
Candace Y Gomez Broughton,
Christopher Downey, PhD,
Deborah Schmiel, PhD,
Dennis Cantellops Paite,
Dennis E Guilfoyle, PhD,
Donald C Obenhuber, PhD,
Dr. Ralph M Bernstein, PhD,
Dr. Robert C Horan, MD,
Ellen P Madigan,
Ephrem Hunde, PhD,
Jacek Cieslak, PhD,
John A Podsadowski,
John S Hartford,
Kalavati Suvarna, PhD,
L Norwood,
Laurie Graham,
Lawrence W Farina,
LCDR Debra Emerson,
Lewis K Antwi,
Linda M Sacco,
Lori A Holmquist,
M Pedgen,
Mariza M Jafary,
Marlene G Swider,
Mary Jeanet Mcgarry,
Megan A Haggerty,
Michael Levin,
Michael Shanks, MS,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Mra V Millarw,
Nicholas C Mendiola,
Obinna R Echeozo,
Pankaj H Amin,
Parul M Patel,
Patricia F Hughes, PhD,
Pete Amin (Pankaj),
Priscilla M Pastrana,
Ramon E Martinez,
Ranjani Prabhakara,
Rebecca Rodriguez,
Reyes Candau Chacon, PhD,
Robert J Martin,
Rose Ashley,
Russ E Davis,
Scott R Nichols, PhD,
Sean R Marcsisin,
Stacey S Degarmo,
Svetlana A Shestopal,
Vijaya L Simhadri,
Wayne E Seifert,
William M Rennells,
Xianghong Jing (Emily), PhD,
Yehualashet A Gessesse,
Zhong Li, PhD
Rashmi Rawat, PhD's Documents
Publish Date | Document Type | Title |
---|---|---|
July, 2010 | FDA 483 | Lonza Biologics, Inc. - Form 483, 2010-07-23 |
May, 2013 | FDA 483 | FUJIFILM Diosynth Biotechnologies Denmark ApS - Form 483, 2013-05-13 |
February, 2013 | EIR | Bristol-Myers Squibb Co., Inc. - EIR, 2013-02-08 |
February, 2013 | FDA 483 | Bristol-Myers Squibb Co., Inc. - Form 483, 2013-02-07 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more